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diseases are a public health priority in Colombia. The aim of this study was to 
estimate the difference of cases and costs from serotype coverage of pneumococ-
cal conjugated vaccines of 10 and 13 serotypes (PCV10 and PCV13, respectively) in 
population under 5 years old in Colombia. Methods: A deterministic model was 
built for a cohort of children born in 2011. The probabilities of incidence, mortality 
and sequelae of pneumonia, meningitis, sepsis, and acute otitis media and clinical 
effectiveness of PCV10 and PCV13 for this population, were determined through a 
systematic literature review. Vaccination scheme 2+1 was included, herd effect of 
42% and population coverage of 84.09% was assumed for both vaccines. The differ-
ences between the evaluated vaccines were estimated in terms of opportunity costs 
and net profit. The study was conducted from the perspective of third-party payers 
and a time horizon of 5 years. Costs were expressed in 2012 USD (exchange rate 
US$1 = $1798.23 COP). Results: A cohort of 652,611 children was assumed. Model 
showed a higher protection with PCV13 in comparison to PCV10. With PCV13 a dif-
ference of 98 prevented deaths for meningitis, pneumonia and sepsis was observed. 
The opportunity cost of having used PCV10 instead of PCV13 was US$20,090,913 in 
the 5 year follow-up (US$4,018,183 per year). Costs related to disease not covered 
by PCV10 are between an annual average of US$4,087,138 to $4,373,597; 82% due to 
lost productivity associated with premature death, 12% to cases of disease and a 
lower percentage to sequelae. ConClusions: PCV13 prevents a greater number 
of deaths and consequences associated with pneumococcal infection compared 
to PCV10, resulting in a considerable economic impact measured in number of 
productive years for Colombia.
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objeCtives: Two Phase 3 clinical trials in patients with Clostridium difficileinfection 
(CDI) showed fidaxomicin to be non-inferior to vancomycin in terms of clinical 
cure, but superior in terms of recurrence. In a pooled, modified intention-to-treat 
analysis of 962 patients, recurrence rates at 28 days were 26.0% (vancomycin), and 
14.1% (fidaxomicin) (p< 0.001) [Crook, et al, 2012]. This analysis aimed to evaluate 
the cost-effectiveness and budget impact of fidaxomicin compared with vanco-
mycin from the perspective of the National Health Service in England. Methods: 
A Markov model was developed with 10-day cycle length, capturing clinical cure, 
first and subsequent recurrence, and treatment outcomes within 1-year. Six patient 
sub-groups were analysed: patients with (a) severe CDI; (b) a first recurrence; (c) 
cancer; (d) aged ≥ 65 years; (e) renal impairment; and (f) receiving concomitant 
antibiotics. Model inputs were derived from published literature and an expert 
panel. Results: Total costs per patient were lower with fidaxomicin than vanco-
mycin for recurrent CDI (£16 535 vs. £16 926), cancer patients (£14 430 vs. £15 373) 
and patients aged ≥ 65 (£14 062 vs. £14 715). Fidaxomicin was associated with higher 
quality-adjusted life years (QALYs) than vancomycin for all patient groups and was 
a dominant option for these three sub-groups. Fidaxomicin was cost-effective at an 
implicit incremental cost-effectiveness ratio (ICER) threshold of £20 000 per QALY 
gained for severe CDI (ICER = £16 529) and patients with renal impairment (ICER 
= £16 693). The annual budget impact of fidaxomicin compared with vancomycin 
would be a saving of approximately £2 500 per patient for the six patient sub-groups 
combined. ConClusions: Fidaxomicin is likely to be a dominant treatment option, 
when compared to vancomycin, for patients with recurrent CDI, cancer or those 
aged ≥ 65, and is likely to be cost-effective at a £20 000 threshold for severe CDI and 
patients with renal impairment.
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objeCtives: This study evaluates the ROI (return on investment) for a PCV13 
vaccination with campaign by corporations for individuals who are 50+ years 
old. Methods: A budget impact analysis was developed considering vaccination 
costs, pneumococcal disease events, and productivity loss from employee absence 
due to sickness or death. Clinical events were calculated using a Markov model 
with individual-level simulation considering a cohort of 1.000 employees and an 
annual discount rate of 5%.Only the portion of employees more than 50 years of age 
was considered. (21% according to Brazilian Institute for Geography and Statistics, 
IBGE). Absence days due to health events were retrieved from national labor leg-
islations. Average wage was retrieved from IBGE 2013. Return on Investment was 
calculated as the time until savings from the cost of productivity gains exceeds 
investment in a vaccination program. Results: A campaign for 206 employees 
50+ years old cost BRL 31.724 and in the first 2 years the return will be BRL 15.449 
due to reduction in events and absenteeism and one fewer death. The ROI will be in 
4,17 years. ConClusions: In addition to decreasing productivity loss, death, and 
additional treatment cost, a pneumococcal vaccination campaign for employees 
over 50 years old yields a positive return on investment.
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objeCtives: To find out the average cost of hospitalization and length of hospital 
stay for patients infected with carbapenem-resistant bacteria and compare it with 
and 38/100,000 population/year, respectively. In both countries, the most common 
isolates were C. albicans, C. parapsilosis and C. glabrata. In patients with fluconazole-
resistant isolates, de-escalation resulted in higher cure and survival rates than 
escalation, with cost savings of € 6,880/patient treated in France and € 2,007/patient 
treated in Germany. Regardless of fluconazole sensitivity, de-escalation resulted 
in higher rates of cure and survival than escalation; these benefits were associ-
ated with an additional cost of € 687 and € 1,237 per patient treated in France and 
Germany, respectively. ConClusions: Across all patient groups, de-escalation from 
micafungin improved clinical outcome and survival. This was particularly marked 
in patients with fluconazole-resistant SCI, in whom de-escalation from micafungin 
was cost-saving. Increased costs with de-escalation in the overall population are 
limited and offset by improvement in survival using this strategy.
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objeCtives: Economic evaluations of CHC therapies may be important from health 
plans’ perspectives. Methods: A budget impact model compared annual CHC ther-
apy cost before and after SMV+PR adoption for a hypothetical 1,000,000 member 
plan. The proportion treated for CHC was derived from various publications. Base 
case analyses assumed Current state market share (MS) within treatment-naïve 
and -experienced populations was equally allocated between telaprevir+PR and 
boceprevir+PR while SMV+PR MS was 0%; Future MS was 45%, 45%, and 10%, respec-
tively. CHC therapy costs were estimated based on dosing and administration data 
from US prescribing information and 12/2013 wholesale acquisition costs (assumed 
82 kg person). Population allocation by prior response, disease severity, and treat-
ment duration used trials data. Drug-only costs per member per month (PMPM) and 
per treated CHC member (PTM) were estimated. Sustained virologic response (SVR) 
absolute values from trials were used to report annual cost per SVR. Results: The 
model suggested 234 G1 CHC members treated annually. Total health plan’s budget 
(drug-only costs) was estimated at $1.82 PMPM before and after SMV+PR adoption 
(incremental cost -$0.001 PMPM). Annual total costs were $93,311 PTM in Current 
state and $93,271 PTM in Future (incremental cost -$40 PTM). The model calculated 
the health plan’s annual cost per SVR as $147,105 in Current state and $144,261 in 
Future for total (treatment-naïve and -experienced) population. Sensitivity analy-
ses doubling or halving the CHC population and increasing SMV+PR MS to 15% or 
20% resulted in incremental PMPM drug-only costs of $-0.002 or $0.000 and -$0.001 
or -$0.002, respectively. ConClusions: Modelled drug-only costs results suggest 
that SMV+PR adoption had an incremental impact to a U.S. health plan budget of 
-$0.001 PMPM (sensitivity analysis ranged -$0.002-$0.000 PMPM). When the base case 
considered drug costs plus outcomes, this resulted in a health plan’s total annual 
cost per SVR decrease of $2,844.
PIN29
a dyNamIc hEalth EcoNomIcs aPP: thE budgEt ImPact of adoPtINg thE 
rEcENtly fda aPProvEd hEPatItIs c thEraPy, sofosbuvIr to a uNItEd 
statEs formulary
Lingohr-Smith M., Lin J.
Novosys Health, Flemington, NJ, USA
objeCtives: The objective of this study was to design an app to estimate the budget 
impact of the adoption of Sofosbuvir, a new antiviral hepatitis C (HCV) therapy to a 
formulary in the U.S. Methods: The pharmacy budget impact to a formulary was 
defined as the difference between the cost “with Sofosbuvir” and the cost “without 
Sofosbuvir” for the treatment of the eligible chronically infected HCV population. 
The model takes the following into account: number of HCV infected persons, per-
cent chronically infected, percent diagnosed, percent diagnosed and treated with 
triple therapy, percent covered by insurance, and drug costs. The app may be used 
to estimate the budget impact of the adoption of Sofosbuvir to either a commercial 
or Medicare/Medicaid formulary in each state of the U.S. and in the U.S. overall and 
may be used with iPad, iPhone, other tablets, laptops, and desktops. Results: In 
2013 in the U.S., 4,008,572 persons were estimated to be chronically infected with 
HCV. At a default of 3% of those diagnosed with chronic HCV being treated with triple 
therapy, and with Sofosbuvir having 15% of the market share the total pharmacy 
budget impact was estimated at $11.3 million annually (before adoption: $1,877 
million vs. after adoption: $1,888 million) among those commercially insured in 
the US. This represents a relative increase of 0.6% ($0.005 per member per month 
(PMPM)). Among those who are Medicaid/Medicare insured the budget impact was 
estimated at $5.8 million, also a relative increase of 0.6%. ConClusions: Based 
on current treatment practices of HCV infected persons, the budget impact of add-
ing Sofosbuvir to a U.S. commercial or government health plan formulary is low 
($0.005 PMPM). The impact of increasing HCV screening and treatment rate and the 
potential reduction of medical costs due to Sofosbuvir’s > 90% sustained virological 
response will require future studies.
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objeCtives: Infections produced by Streptococcus pneumoniae have an important 
impact on worldwide health due the high burden of disease they generate; these 
